Expanding the spectrum of triggers in aspirin-exacerbated respiratory disease: sildenafil-associated respiratory symptoms
- 30 January 2026
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (4) , 981-982
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (K24AI180296)
- National Institute of Allergy and Infectious Diseases (U19AI095219)
This publication has 9 references indexed in Scilit:
- Low Prostaglandin E2 but High Prostaglandin D2, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway EpitheliumJournal of Clinical Medicine, 2024
- Exploring the Multifaceted Potential of Sildenafil in MedicineMedicina, 2023
- Updates on immune mechanisms in aspirin-exacerbated respiratory diseaseJournal of Allergy and Clinical Immunology, 2022
- Sildenafil reduces aortic endothelial dysfunction and structural damage in spontaneously hypertensive rats: Role of NO, NADPH and COX-1 pathwaysVascular Pharmacology, 2020
- A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory diseaseJournal of Allergy and Clinical Immunology, 2019
- Aspirin-Exacerbated Respiratory DiseaseNew England Journal of Medicine, 2018
- Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory diseaseJournal of Allergy and Clinical Immunology, 2015
- Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responsesJournal of Allergy and Clinical Immunology, 1999
- Inhaled PGE2 Prevents Aspirin-Induced Bronchoconstriction and Urinary LTE4 Excretion in Aspirin-Sensitive AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1996